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While IL-1 was initially described as a lymphocyte-activating factor (1), subse-
quent studies (2, 3) have shown that IL-1 regulates a variety of nonlymphoid
cells involved in the inflammatory response. Prominent among these are connec-
tive tissue cells. While early studies demonstrated the ability ofIL-I to stimulate
proliferation by human dermal fibroblasts (4-6) and collagenase production by
human synovial fibroblasts (7-9), more recent studies have shown matrix resorp-
tive effects on articular cartilage (10) and bone (11-13) in organ culture.
When one fractionates human monocyte culture supernatants by IEF, three
major charged species having pI of 6.8, 5.4, and 5.2 are consistently observed
whether the fractions are assayed on murine thymocytes or connective tissue
cells (4, 5, 14). The pI 6.8 species, which isresponsible for -90% ofthe biological
activity found in human monocyte culture supernatants, has been purified (15,
16), and amino acid sequence analysis (16, 17) shows that it is encoded by an
abundant mRNA, the cDNA ofwhich is now referred to as IL-1,Q (17, 18). The
pl 5.2 and pl 5.4 species have recently also been purified (19) and amino acid
sequence of these species (19) shows that they are encoded by a tenfold less
abundant mRNA, the cDNA of which is now referred to as IL-la (17). Even
with the insertion of numerous gaps in the amino acid sequences to maximize
homology, the two human IL-1 species have only 30% of their amino acid
residues in common (17). Nevertheless, comparison ofpure pI 6.8 IL-1 and pure
pl 5.4/5.2 IL-1 on murine thymocytes shows them to be equally potent with
half-maximal stimulation seen at concentrations of 20-34 pM (19). When these
same native purified IL-1 species are tested for their ability to stimulate human
dermal fibroblast proliferation, they are found to be even more potent, but
equally so, with concentrations of only 1-3 pM required for half-maximal
stimulation (20).
Recently it has been reported that murine (21) and human (22) lymphoid lines
and murine 3T3 cells (23) bear low-affinity receptors for human pI 6.8 IL-1 (IL-
10) with Kd of ~200-500 pM (21-23). In particular, the murine T lymphoma
line, LBRM-33 IA5, which half-maximally produces IL-2 in response to 10-'4
M IL-1(3, was reported (21, 23) to have 250 sites per cell of similar low affinity.
Accordingly, less than a single IL-1 receptor per cell would be occupied when
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half-maximal IL-2 production is observed in response to IL-1 . This discrepancy
calls into question the physiological role of the low-affinity receptors and suggests
that considerably higher affinity receptors most likely mediate the biological
effects of IL-1 on these target cells.
In the current report, a high-affinity IL-1 receptor is identified on human
embryonic lung fibroblasts. As previously noted in the case ofhuman rheumatoid
synovial cells (20), these cells produce prostaglandin E2 at low picomolar concen-
trations of both IL-1 species, with ^-3 pM IL-10 or ^" 10 pM IL-la required for
half-maximal stimulation . Equilibrium binding studies with labeled IL-10 give a
Kd/Ki of 10 pM for IL-1(3, and IL-la can bind to the same site with approximately
fivefold lower affinity, that is, with a Ki of 50 pM. These findings suggest that
the biological effects observed at low picomolar concentrations of IL-1 are
mediated by receptors with considerably higher affinity than previously reported
and are consistent with the existence ofa single receptor mediating the biological
effects of both IL-1 species.
Materials and Methods
Culture ofHuman Embryonic Lung Fibroblasts (MRC-5).
￿
Human embryonic lung fibro-
blasts were obtained from the American Type Culture Collection, Rockville, MD, and
cultured in 450-cm' roller bottles or in 150-cm' tissue culture flasks in culture medium
consisting of DME containing 10% FCS, 4 mM glutamine, 25 mM Hepes, 100 U/ml
penicillin, and 100 jig/ml streptomycin at 37 °C in a humidified atmosphere of 7 .5%
C02/air. The cells were passaged weekly and the medium was changed two additional
times weekly. Cells passaged up to four times in our laboratory were used for these studies.
In preparation for assays, the cells were removed with 0.5% trypsin/0 .2% EDTA, diluted
into fresh culture medium, and plated at a density of 2 x 104 cells/well in 24-well plates
(No. 3524; Costar, Cambridge, MA) or at a density of 105 cells/well in six-well cluster
plates (No. 52795, Nunc, Roskilde, Denmark). Cell number was determined by counting
the trypsinized cells in a hematocytometer.
Measurement ofProstaglandin E2 (PGE2) in Response to IL-1 Species.
￿
24 h after MRC-5
cells had been subcultured into 24-well plates, the culture medium was removed from
each well by gentle aspiration and was replaced with 0.5 ml of fresh culture medium
containing known concentrations of purified IL-1 species (see below). After incubation
for 18-20 h, the culture medium was removed, centrifuged at 400 g, and frozen at -70 ° C
until assayed. To measure PGE2, 300 jl of each sample was extracted three times with 1
ml of ethyl acetate (HPLC grade, Fischer Scientific Co., Pittsburgh, PA). The extracts of
each sample were pooled, taken to dryness under a stream of dry nitrogen, and taken up
in 50,l of DME/10% FCS. Preliminary experiments with tritiated PGE2 showed that 85-
90% of the labeled material was successfully extracted from culture medium by this
procedure. PGE2 was then assayed by RIA as previously described (24) and the results
were expressed as picograms of PGE2 per culture. Extracts of fresh medium containing 1251-IL-10 gave no signal in the RIA for PGE2, thus permitting assessment of the specific
biological activity of the radioligand.
Purification ofNative Human IL-10 and IL-la.
￿
Native IL-10 (pI 6.8) and IL-la (pI 5 .4)
were purified from mononuclear cell culture supernatants as previously described (16,
19). The IL-1 species were pure, as determined by SDS-PAGE and silver staining (19).
The protein concentration of each of the IL-1 preparations was determined by peak
integration at 214 nm as the IL-I species eluted from a reverse-phase HPLC column, as
previously described (19). The integration function ofthe detection system was calibrated
by chromatographing known amounts of pure RNase and constructing a linear calibration
plot of integration units versus amount of protein injected. This method has been
previously validated by amino acid analysis of purified IL-I (16).
Preparation of 1251-IL-1,8.
￿
Pure IL-10was concentrated to 0 .25-0.50 mg/ml by ultrafil-72
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tration on YM-10 membranes (Amicon Corp., Danvers, MA) and desalted into 20 mM
sodium phosphate buffer, pH 7.95, containing 100 ug/ml of PEG (mol wt = 8,000). 5-
10 Wl of protein solution was reacted with 2 mCi of monoiodo Bolton-Hunter reagent
(New England Nuclear, Boston, MA) for 3 h on ice as previously described (25). These
conditions usually resulted in labeling of ^-50% of the IL-1 molecules. The radioligand
was then extensively reisolated by methods to be published in detail elsewhere.' Briefly,
the reaction mixture was first chromatographed on an HPLC gel filtration column to
remove the unincorporated label. Subsequent HPLC hydrophobic interaction chromatog-
raphy of the labeled IL-1# preparation resulted in complete resolution of labeled from
unlabeled IL-1#. The labeled IL-1,8 was then collected, pooled, and desalted by HPLC
gel filtration chromatography. The amount of protein in the '25I-IL-I0 preparation was
determined by integration of the absorbance profile obtained at 214 nm during the final
gel filtration chromatography step in comparison with known amounts of RNase, as
described above.
Determination ofRadioligand Bindability.
￿
To determine the percentage of radioligand
that was bindable, -10,000 counts of ' 25I-IL-1/3 was added to 0.5 ml of binding buffer
(see below) with or without 1 nM unlabeled IL-Is . The solutions were then successively
incubated with a series of highly confluent cluster-well cultures of MRC-5 fibroblasts for
1 h each at room temperature with gentle continuous mixing on a platform rocker. The
solutions were removed after each adsorption step, counted, and then transferred to fresh
cultures of fibroblasts. Counts remaining in solution after each adsorption step were then
plotted as a function of passage number.
Direct and Competitive Binding Experiments.
￿
Before direct binding experiments, the
MRC-5 fibroblasts were cultured in six-well cluster plates as described above. After 4-6
d of culture, when the cell density was ^-2 X 106 cells/well, the medium was removed
from each well and replaced with 0 .5 ml of binding buffer (DME/5% FCS/0.2% sodium
azide) containing measured amounts of '251-IL-1(3 with or without a 50-fold molar excess
ofunlabeled IL-1#. The plates were then incubated at 20°C for 2 h with gentle continuous
mixing. After the incubation period was completed, the supernatants were removed with
a Pasteur pipette, counted, and taken as a measure of free counts. In preliminary
experiments, the number of free counts was closely approximated by subtracting the
number of counts bound (see below) from the total number of counts added (± 95%).
Therefore, in subsequent experiments, the number of free counts was obtained by using
a computer program (see below) that subtracted the number of bound counts from the
total number of counts added. To determine the number of counts bound, the plates
were washed by dipping them rapidly three times in 3 liters of PBS. Preliminary experi-
ments showed that additional rapid washes did not further reduce the number of counts
remaining with the cell monolayer. The bound counts were then solubilized with the
addition of 0.3 ml of 2.5 M NaOH per well, transferred to a scintillation vial, and counted.
The number of counts bound in the presence of excess unlabeled IL-1(3 was taken as a
measure of nonspecific binding. The number of specific counts bound was calculated by
subtracting the number of nonspecific counts bound from the total number of counts
bound.
In competitive bindin
￿
experiments, the cells were overlayed with 2.0 ml of binding
buffer containing 4 pM A5I-IL-1(3 and known amounts of one of the following unlabeled
ligands: IL-I#, IL-la, human native tumor necrosis factor a (reference 26 ; kindly provided
by Dr. Berish Rubin, New York Blood Center, NY), human rIL 2 (Amgen Corp.,
Thousand Oaks, CA), human rIFN-y (Amgen Corp), or bovine acidic fibroblast growth
factor (references 27, 28; kindly provided by Dr. Kenneth Thomas, Merck Research
Laboratories, Rahway, NJ). These solutions were then incubated on fibroblasts for 2 h at
20'C and the plates were then washed, solubilized, and counted as detailed above.
Assessment of Equilibrium.
￿
To determine the time necessary for binding of IL-1 to
reach a steady state, 10 pM '2'I-IL-1/3 in binding buffer was added to replicate wells at
time 0 . At measured intervals, duplicate wells were washed, solubilized, and counted as
' Schmidt, J. A., and J. Chin. Preparation and isolation of monoiodinated human interleukin 10.
Manuscript in preparation.CHIN ET AL.
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detailed above . A second series of replicate wells, which were overlayed with 10 pM
'261-
IL-1/3 and 500 pM unlabeled IL-la at time 0, were harvested in parallel with the first
series of wells to determine the amount of nonspecific binding at each time point. Specific
counts bound was then plotted as a function of time.
To assess the proportion of bound counts that were dissociable, MRC-5 cells were
incubated with 10 pM '25I-IL-Is for 2 h. The cells were then washed, solubilized, and
counted to determine the number of counts bound. Replicate wells were washed and
treated with 200,ul of 2% acetic acid in 0.14 M NaCl (pH 2 .5) for 1 min. The supernatant
was then removed and counted. The number of counts stripped by acetic acid was taken
as a measure of surface-bound radioligand. To ascertain whether the counts removed
with acetic acid represented intact radioligand, an aliquot (100 ul) was precipitated with
10% TCA on ice with 100 tig of BSA added as a carrier. The pellet was washed three
times with ice-cold 10% TCA and counted.
Crosslinking Exberiments.
￿
MRC-5 fibroblasts were overlayed with binding buffer con-
taining 100 pM ' SI-IL-1 fl alone or together with one of the following unlabeled ligands:
1 nM IL-1,5, IL-la, human rIL 2, human rIFN--y, or human TNF-a. These solutions
were then incubated on fibroblasts for 2 h at 20° C as described above. At the conclusion
of the incubation period, the plates were washed as described above and then incubated
in PBS containing 0 .1, 0.2, 0.5, or 1 .0 mg/ml of the homobifunctional crosslinker
disuccidimidyl suberate (DSS;2 Pierce Chemical Co., Rockford, IL) for 1 h at 20 ° C.
Subsequently, the plates were washed three times in fresh PBS and the cells were scraped
into 50 ul of Laemmli sample buffer containing 15% SDS with or without 10% 2-ME.
The samples were boiled for 5 min and electrophoresed on a 7.5% homogeneous gel for
15 h at 5 mA and for 3 h at 20 mA using the discontinuous buffer system of Laemmli.
The gels were fixed, stained with Coomassie Blue, dried, and exposed to Kodak XAR-5
film for 7-10 d at -70 °C. The gels were calibrated with the following proteins of known
molecular mass: myosin, 200 kD; 0-galactosidase, 116.2 kD; phosphorylase B, 92.5 kD;
BSA, 66.2 kD; OVA, 45 kD; carbonic anhydrase, 31 kD; soybean trypsin inhibitor, 21 .5
kD; and lysozyme, 14.4 kD .
Data Analysis.
￿
Equilibrium binding data were analyzed by the 1986 version of the
Ligand (29) family of programs on an appropriately equipped IBM personal computer.
Ligand is a nonlinear-curve fitting program that uses the mass-action equation and a
weighted least squares statistical algorithm to determine the Kd, the molar concentration
of receptors (R), and nonspecific binding (N). The power of this software as compared
with manual or graphical methods has been described in detail elsewhere (29) . The salient
features of the program with respect to the current study are (a) the ability to compensate
for radioligand bindability; (b) the ability to test and compare the goodness of fit obtained
with alternative models, e.g., one site versus two site models; and (c) the ability to
simultaneously analyze displacement curves obtained for two different unlabeled ligands,
e.g., IL-1,0 and IL-la, within an experiment to obtain a more precise and accurate
estimate ofthe parameters shared in common, such as binding capacity and N. Competitive
binding data obtained for unlabeled IL-1(3 and IL-1 a were analyzed using a two ligand/one
site model and by equating the nonspecific binding parameters (N1, N2) for both ligands.
Graphical output of direct binding data in the Scatchard format was also performed by
Ligand.
Plotting and curve fitting of bioassay data and plotting of theoretical binding curves
was performed by an IBM PC using Parafit II (Dynacomp, Boston, MA), a nonlinear
parameter regression program.
Results
To determine if human embryonic lung fibroblasts would be suitable target
cells for IL-1-R binding studies, it was first determined whether they were
biologically responsive to low picomolar concentrations of IL-1 as has been
2 Abbreviations used in this paper:
￿
DSS, disuccidimidyl suberate; N, nonspecific binding; R, molar
concentration ofreceptors.74
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FIGURE 1 . Prostaglandin E2 production by MRC-5 human embryonic lung fibroblasts in
response to increasing concentrations of native human IL-10 (filled triangles) or IL-la (open
triangles). The means(± SEM) of triplicate determinations are plotted.
recently demonstrated (20) for other types of normal human connective tissue
cells. As shown in Fig. 1, these cells responded in saturable fashion to low
picomolar concentrations ofnative IL-10 (pl, 6.8) and IL-1a (pl, 5.4) by secreting
five- to eightfold higher amounts of prostaglandin E2. IL-1,0 and IL-1a stimulated
the same maximum level of PGE2 secretion. In three experiments, half-maximal
stimulation of PGE2 secretion was seen with IL-1,# and IL-la at concentrations
of 3 ± 1 .2 pM and 10 ± 2.3 pM (± SEM), respectively. These results suggested
that MRC-5 fibroblasts possess functional, high-affinity receptors for both IL-1/3
and IL-1a.
To identify the receptor site for 11--:10, native IL-lei was labeled with 1251_
Bolton-Hunter reagent. The Bolton-Hunter technique was chosen because pre-
liminary experiments with other labeling techniques, all of which involved the
use of oxidizing agents, showed that even brief exposure of IL-1 to oxidants
alone led to its complete loss of bioactivity in the murine thymocyte assay
(Limjuco, G., and J. Schmidt, unpublished observations). The conditions of the
Bolton-Hunter reaction were chosen so that -50% of the molecules were labeled.
The labeled IL-1 molecules were then completely separated from the unincor-
porated Bolton-Hunter reagent by HPLC gel filtration chromatography and
from the unlabeled IL-1 molecules by HPLC hydrophobic interaction chroma-
tography (see Materials and Methods). As shown in Fig. 2A, HPLC gel filtration
chromatography was used as the last step in the isolation procedure to desalt the
radioligand. A sharp, symmetrical peak was detected at 214 nm, which corre-
sponded with radioactivity . The specific radioactivity of the labeled material was
calculated directly by using the absorbance at 214 Inn as a measure of protein
concentration (see Materials and Methods). The results of such calculations
consistently gave values between 2,000 and 2,400 Ci/mmol, indicating that the
labeled material represented monoiodo IL-1,Q. SDS-PAGE and autoradiographyCHIN ET AL .
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FIGURE 2 . Isolation of monoiodo IL-1,Q . Native human IL-10 was labeled with Bolton-
Hunter reagent and the iodinated species were separated from free-label andunlabeled IL-10
by HPLC gel filtration and hydrophobic interaction chromatography (not shown) and then
desalted by HPLC gel filtration chromatography (A) . The absorbance of the effluent was
monitored at 214 nm and the radioactivity (dpm) of 30-s fractions was measured in a gamma
counter . SDS-PAGE and autoradiography of the labeled product is shown in B with the
positions of molecular mass markers indicated by arrows .
of the purified radioligand (Fig . 2B) showed that all of the counts were associated
with a single 18 kD band having the same mobility as human IL-1,0 .
When various preparations of the purified radioligand were tested for bioac-
tivity on either murine thymocytes or MRC-5 fibroblasts, they were found to
retain 40-50% of the specific bioactivity of the unlabeled material (data not
shown) . More relevant to the calculation of the equilibrium binding constant
(30), the radioligand preparations were tested for bindability to MRC-5 fibro-
blasts by successively adsorbing a limiting amount of radioligand to cultures of
MRC-5 fibroblasts in the presence and absence of a 50-fold molar excess of
unlabeled IL-10 . Theamount of radioligand removed by the cultures minus that
amount removed in the presence of excess unlabeled ligand was calculated and
taken as a measure of specifically bindable radioligand. As shown in a represent-
ative experiment in Fig . 3, 41% of the total initial counts and55% of the counts
remaining after five passages in the presence of excess unlabeled ligand were
specifically bound. These percentages represent minimum and maximum esti-
mates of bindability depending on whether damaged radioligand is selectively
lost during the transfer of labeled material from well to well . The radioligand
that was not adsorbed to cells nevertheless remained TCA precipitable (>95%),
thus indicating that proteolysis of radioligand during the course of the experi-
ment was not contributing to decreased bindability . A factor of 0 .5 was therefore
used to correct the number of free counts in the direct binding experiments (see
below) .
To assess the time required for binding of 1251-IL-1,Q to reach equilibrium,76 HIGH-AFFINITY INTERLEUKIN I RECEPTORS ON FIBROBLASTS
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Bindability of labeled IL-1,8. 1251-IL-10 (7,000 cpm) was serially incubated for I
h with cultures of MRC-5 human embryonic lung fibroblasts alone (open circles) or in the
presence of I nM unlabeled IL-I fl (filled circles). The binding conditions are specified in
Materials and Methods. The supernatants were removed after each adsorption step and
counted, and the means of duplicate determinations are plotted. The difference between the
mean number of free counts obtained with labeled IL-10 aloneand the mean number of free
counts obtained in the presence of excess unlabeled IL-Ifl wascalculated aftereach adsorption
step (squares) and taken as a measure of specifically bindable radioligand. The minimum
bindability in this experiment was 41% (2,950 cpm/7,000 cpm) and the maximum bindability
was 55% (2,950/5,250 cpm).
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FIGURE 4.
￿
Kinetics of binding of 1211-IL-10 to human embryoniclung fibroblasts. Replicate
cultures were incubated with 10 PM 125I-IL-1,8 alone or in the presence of excess (500 pM)
unlabeled IL-I#as detailed in Materials and Methods. Duplicate cultures from each set were
rapidly washed and solubilized at the indicated times. Specific counts bound were calculated
by subtracting counts bound in the presence of excess unlabeled IL-I# from counts bound
with '25I-IL-1,B alone.
replicate cultures of MRC-5 fibroblasts were incubated with 10 pM 125I-IL-1(3 at
20'C in the presence of 0.2% sodium azide. At various times, the cell layers in
duplicate cultures were rapidly washed and solubilized to determine the total
number of counts bound. The nonspecific-binding component was determined
in a parallel series of cultures that were incubated with radioligand and a 50-fold
molar excess of unlabeled IL-1,Q (see Materials and Methods). As shown in Fig.
4, specific binding proceeded moderately rapidly under these conditions and
reached a plateau within two hours. By comparison, binding at 4°C proceeded
slowly and had not yet reached a steady state by 4 h of incubation (data not
shown). To determine if the cell-associated radioligand represented surface-
bound or internalized radioligand, stripping experiments were performed. AsCHIN ET AL.
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TABLE I
Recovery ofBound 12'I-IL-1(3from MRC-5 Fibroblasts
Cultures ofMRC-5 fibroblasts were incubatedwith 10 pM 12-11-IL-I# for
2 h at 20'C and washed.
Total counts bound is the number of counts recovered after the 2-h
incubation period when the cell layer was solubilized with 2 M sodium
hydroxide. The mean of triplicate determinations is shown.
Replicatecultures were washed and treated with 2% acetic acid,pH 2.5,
for 1 min. The supernatants were removed and counted. The mean of
triplicate determinations is shown. The numbersin parentheses indicate
the percentage of total cpm bound that were stripped from the cells
under these conditions.
The material stripped with acetic acid was supplemented with TCA
(10%, final concentration) and BSA (100 ag/ml, final concentration)
and allowed to stand on ice for 10 min. The precipitate was washed
three timeswith cold 10% TCA.The mean oftriplicate determinations
is shown. The numbers in parentheses indicate the percentage of cpm
stripped with acetic acid that were TCA precipitable. The radioligand
before incubation with cellswas 98% TCA precipitable.
shown in Table I in two experiments, 96% and 85% of the counts specifically
bound by 2 h at 20°C were removed by a 1-min exposure of the cells to 2%
acetic acid, 0.14 M NaCl, pH 2.5, and of those counts removed, ?95% were
TCA precipitable. These results indicate that little or no internalization or
degradation of the bound radioligand had occurred under the assay conditions
employed.
The results ofa representative direct binding experiment are shown in Fig. 5
in which increasing concentrations of 121I-IL-1f were incubated with replicate
cultures of MRC-5 fibroblasts for 2 h at 20°C in the presence of sodium azide.
The nonspecific-binding component was determined by incubating a parallel
series of cultures with radioligand in the presence of a 50-fold molar excess of
unlabeled IL-I#. A plot of specific counts bound as a function of radioligand
concentration (Fig. 5A) indicates that binding is dose-responsive and saturable.
Using a computer-based program using the mass action equation and taking into
account the bindability of the radioligand (Ligand, see Materials and Methods),
the data in this and two additional direct binding experiments (Table II) were
best fit by a single site model with a mean Kd of 8.4 ± 4.1 pM (± SEM). A two
site model with high- and low-affinity binding sites differing in affinity by 2-
1,000-fold, fit these data considerably less well (data not shown). A plot of the
computational results in the Scatchard format is shown in Fig. 5B. The average
number of sites per cell was 3,100 ± 1300 (± SEM). This value was in good
agreement with that obtained by dividing the number ofmolecules of 125I-IL-1#
bound at saturation by the number of cells per culture (2,100 ± 600 sites/cell).
The results of a representative competitive binding experiment are shown in
Fig. 6. In these experiments, replicate cultures were incubated with a limiting
concentration of "5I-IL-1(3 (4 pM) and increasing concentrations (0.2-500 pM)
of either unlabeled IL-1# or IL-la for 2 h at 20°C. Competition by both
'25I-IL-1,8 Exp. 1 Exp. 2
Total cpm bound* 2,042 2,278
cpmstripped by acetic acid (%)$ 1,965 (96) 1,942 (85)
cpmprecipitated by 10% TCA§ 1,865 (95) 1,876 (97)78 HIGH-AFFINITY INTERLEUKIN 1 RECEPTORS ON FIBROBLASTS
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￿
Direct binding of '251-IL-113 to human embryonic lung fibroblasts. (A) Increasing
concentrations of radioligand were incubatedwith cultures of MRC-5 fibroblasts alone (trian-
gles) or in the presence of a 50-fold molar excess of unlabeled IL-10 (squares) as detailed in
Materials and Methods. Specific counts bound (circles) were calculated by subtracting counts
bound in the presence of excess unlabeled ligand from counts bound in the presence of
radioligand alone. The radioligand concentration (pM) hasbeen corrected for bindability. (B)
The data shown in A were analyzed by Ligand and the results were plotted in the Scatchard
format. The Kd obtained in the experiment shown was 15 pM.
Summary ofResults Obtained in Direct and Competitive Binding Experiments
* Direct binding experiments were performed by incubating 0.2-100 pM 1251-IL-IS with MRC-5
fibroblasts as detailed in MaterialsandMethods. The Kdand receptor concentration were calculated
by Ligand, as described in Materialsand Methods.
Competitive binding experiments were performed by incubating 4 pM 1251-IL-113 and 0-500 pM
unlabeled IL-113 or IL-la with MRC-5 fibroblasts, as described in Materials and Methods. The Ki
and receptor concentration were calculated using Ligand anda two ligand/one site model.
unlabeled IL-1(3 and IL-la was observed. Computer-based analysis of the com-
petitive binding data obtained for IL-1,# or IL-la again showed that each set of
data was best fit by a single site model. Using a single site/two ligand model,
Exp.
Direct binding*
Kd
Receptor con-
centration
(sites/cell)
Competitor
Kl of IL-113
Competitive
K; of IL-la
binding,
Receptor con-
centration
(sites/cell)
PM PM PM
1 6.5 1,500 14 23 3,500
2 3.7 2,700 6.8 74 3,200
3 15 5,100 13 53 1,100
Mean ± SEM 8.4 ± 4.1 3,100 ± 1,300 11.2 ± 2.8 50 ± 18 2,600 ± 9207
m°
N
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￿
Competitive binding of 1251-IL-1# to human embryonic lung fibroblasts. 4 pM 1251-IL-ls was incubated with human embryonic lung fibroblasts in the presence of the
indicated concentrations of unlabeled IL-1,B (filled triangles), IL-la (open triangles), human
IL-2 (open circle), IFN-,y (filled circle), tumor necrosis factor a (open square), or bovine acidic
fibroblast growth factor (filled square) as detailed in Materialsand Methods. Thecompetitive
binding data obtained for unlabeled IL-I# and IL-la were analyzed by Ligand and tabulated
in Table II. The K; values obtained for IL-1/3 and IL-la in the experiment shown were 13
and 53 pM, respectively.
analysis of three experiments (Table 11) gave a mean Ki of 11 ± 2.8 pM (± SEM)
for IL 1#, in good agreement with the Kd obtained in the direct binding
experiments. IL-1a competed less well than IL-1,Q with a mean Ki of 50 ± 18
pM . The same preparations of native IL-1,Q and IL-la used in these experiments
were nevertheless found to be equally active on murine thymocytes with half-
maximal stimulation observed at 20 pM as previously reported (19). The lower
affinity observed for IL-1a therefore did not appear to be the result of partial
inactivation of these preparations as compared with IL-I f3. Human IL-2 and
human IFN-y gave no inhibition whatsoever at a concentration of 1 nM (Fig. 6).
Human tumor necrosis factor a, which shares some of the same biological
properties of IL-1 with respect to connective tissue cells (31), did not compete.
Bovine acidic fibroblast growth factor, a molecule which is homologous with
human IL-l,d at the amino acid level (27, 28), similarly gave no inhibition of
binding at a concentration of 1 nM (Fig. 6).
To examine the molecular weight of the IL-1-R molecule and its potential
subunit composition, MRC-5 fibroblasts were incubated with 100 pM 125I-IL-1(3
for 2 h at 20°C, washed, and incubated with the homobifunctional crosslinker,
DSS, for an additional 1 h at room temperature. Afterwards, the cells were
washed, solubilized in Laemmli sample buffer with or without reducing agent,
and analyzed by SDS-PAGE. As shown in Fig. 7 at a DSS concentration of 0.2
Mg/Ml, 1251-IL-1,0 was associated with a dominant band of 98 kD when electro-
phoresed under reducing (lane 1) or nonreducing (lane Z) conditions. A fainter
band of ^-200 kD was also seen in this and one additional experiment. Fainter
bands, seen at the top of the running gel, probably represent aggregated material
since they constituteda proportionately larger percentage of the labeled material
when higher concentrations of crosslinker were used (data not shown) . A lower
concentration of crosslinker (0.1 mg/ml) gave considerably fainterbands but was
otherwise identical to the result obtained at 0.2 mg/ml. Labeling of both the 98
and 200 kD bands was completely blocked by performing the labeling in the80
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FIGURE 7 .
￿
Crosslinking of "II-IL-10 to human embryonic lung fibroblasts . "5I-IL-IS (100
pM) was incubated with MRC-5 fibroblasts alone (lanes 1 and 2) or in the presence of 1 nM
unlabeled IL-10 (lane 3), IL-la (lane 4), human IL-2 (lane 5), IFN-y (lane 6), or TNF-a (lane
7), as detailed in Materials and Methods . The cultures were then treated with DSS and
solubilized in sample buffer with (lane 1) or without (lanes 2-7) reducing agent before SDS-
PAGE andautoradiography . The positions of molecular mass markers are indicated at right .
presence of 1 nM IL-10 (lane 3) or 1 nM IL-la (lane 4) . No competition was
observed with I nM human rIL-2 (lane 5), human rIFN--y (lane 6), or human
tumor necrosis factor a (lane 7) .
In Fig . 8, the bioassay results plotted in Fig. 1 have been fitted (see Materials
and Methods) and compared with theoretical binding curves generated by the
mass-action equation using the mean values for Ki and R determined in the
competitive binding experiments (Table II) . This analysis shows that the binding
and biological response curves are parallel for both IL-1 species and that -10-
15% of the binding sites must be occupied by IL-10or IL-lafor either to induce
a half-maximal biological response .
Discussion
The current work identifies a high-affinity receptor for native human IL-1,0
and IL-la on normal human embryonic lung fibroblasts . While others (21-23)
have employed Bolton-Hunter reagent to prepare 125I-IL-10, the preparation of
radioligand in the current study differs from previous reports in the following
important respects . First, advantage was taken of the additional hydrophobicity
resulting from the covalent modification of IL-1(3 by Bolton-Hunter reagent so
that labeled IL-1 molecules could be separated from unlabeled molecules by
HPLC hydrophobic interaction chromatography . This approach provided ma-
terial of higher specific radioactivity and permitted unambiguous assessment of
the biological activity of the radioligand preparation . The retention of bioactivity
obtained with our procedure compares favorably with previous results using the
Bolton-Hunter technique and gel filtration chromatography alone where <5%
of bioactivity was retained (21) . Second, the radioligand was purified in the
absence of carrier protein (21, 23) so that the specific radioactivity (Fig . 2) ofE
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FIGURE 8.
￿
Comparison of thebiological response and binding curves for native human IL-
la (A) and IL-1 fl (B). The bioassay data plotted in Fig. 1 were fitted by Parafit II software as
described in Materialsand Methods. Thepositions ofthedata points used by thecurve-fitting
routine are indicated by open (IL-1a) andfilled (IL-10) triangles, respectively. Three of the
data points on the plateau of the IL-10 dose-response curve were omitted from the analysis.
The solid curves to the rightin each panel are computer-generated theoretical binding curves
for IL-la and IL-I# usingthe mass-action equation and the mean binding parameters (Ki, R)
obtained from the competitive binding experiments tabulatedin Table 11.
the purified radioligand could be determined directly. Third, the issue of
bindability (Fig. 3) was addressed and appropriate corrections in the calculations
have been made. Attempts to obtain higher bindability by labeling IL-1(0 with
various phosphokinases, such as has been recently reported for human 1FN-'Y
(32), were unsuccessful (Siekierka,J., andJ. Schmidt, unpublished observations).
After establishing a set of steady-state conditions (Fig. 4) under which there
was little or no evidence of internalization (Table I), the equilibrium binding
constant ofthe receptor was determined in twocomplementary ways. First, direct
binding experiments (Fig. 5, Table II) were performed which, when corrected
for bindability, gave a mean Kd of8.4 pM for IL-10. Second, competitive binding
experiments (Fig. 6, Table II) were performed which gave a mean Ki of 11 pM
for IL-1# and 50 pM for IL-la. Equilibrium binding measurements based on
competitive binding experiments are influenced to a much lesser extent by the
bindability of the radioligand (30). That the Ki obtained for IL-10 in the
competition experiments is in good agreement with theKd obtained in the direct
binding experiments therefore provides confirmatory evidence that the estimate
of bindability is accurate and that the bindable radioligand interacts with the82
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receptor in a native or a near-native fashion. The binding curves obtained in
both the direct and competitive binding experiments were best fit by models
specifying a single family of receptors with the same affinity for IL-1(3 or IL-Ia.
Thus, unlike other receptor systems (e.g., the IL-2-R system; see reference 33),
there is no evidence for high- and low-affinity IL-1-R on human lung fibroblasts.
The equilibrium binding measurements are important because they identify a
receptor of sufficiently high affinity for native human IL-1f and IL-1a to mediate
the biological effects of these mediators on connective tissue cells. Only 3 pM
IL-1,0 or 10 pM IL-la was required to half-maximally activate MRC-5 human
embryonic lung fibroblasts, as determined by prostaglandin E2 secretion (Fig. 1).
In comparison, the equilibrium dissociation constants for IL-10 and IL-la, as
determined in direct and competitive binding experiments, were found to be
8.4-11 and 50 pM, respectively (Figs. 5 and 6; Table I1). Two conclusions can
be drawn from a comparison of these data (Fig. 8). First, as found in other
receptor systems (34), the occupation of a portion of the receptors by either IL-
I# or IL-la results in a proportionately larger biological response. For example,
occupation of 11% of the available sites by IL-1f3 or 15% of the sites by IL-la
gave half-maximal increases in prostaglandin E2 secretion. The three- to five-
fold amplification observed on normal human fibroblasts is nevertheless in
marked contrast to the extraordinary level of signal amplification (100-100,000-
fold; references 21-23, 35) that has been proposed for a variety of lymphoid
lines (see below). Second, since the three- to four-fold difference in the specific
bioactivities of IL-If and IL-la on MRC-5 fibroblasts (Fig. 1) is similar, within
experimental error, to the fivefold difference in the binding affinity for IL-1(3
and IL-la, the data are consistent with a single IL-1-R mediating the biological
properties of both IL-1 species. The failure to obtain a better fit of the data with
a two-site model would also tend to rule out the existence of a second site with,
e.g., higher affinity for IL-la and lower affinity for IL-1,Q. However, crossreac-
tivity by itself is not sufficient evidence to rule out the existence of a second IL-
1-R site . For example, insulin-like growth factors I and 11, which have similar
biological properties and specific bioactivities, have biochemically distinct but
crossreactive receptors (36). Quantitative direct and competitive binding studies
as well as crosslinking studies with labeled IL-1a will be required before the
possibility of a second binding site can be definitively eliminated.
The crosslinking studies (Fig. 7) suggest that the molecular mass of the IL-1
receptor is ^-80 kD, in agreement with the results of a previous study (21)
performed on murine cells. As in the competitive bindingexperimentsperformed
on whole cells, labeling of the 80-kD species was blocked by both IL-10 and IL-
la, whereas IL-2, IFN-y, and TNF failed to blockcrosslinkage at a concentration
of 1 nM. There was no evidence of subunits bridged by disulfide bonds in that
the molecular mass of the receptor was not affected by the addition of reducing
agents. A high molecular mass band at ^-200 kD was also consistently observed.
Like the 80-kD species, this receptor species bound both IL-1,Q and IL-la
specifically and was not affected by the addition of reducing agent. This band
can represent a second receptor species or, more likely, a receptor dimerformed
upon the addition of crosslinking reagent. The formation of dimers in the case
of a low-abundance receptor would suggest that the receptor is laterally mobileCHIN ET AL.
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in the plain of the membrane and that local aggregation of receptors may occur
after ligand binding.
The value obtained in the current study for the equilibrium dissociation
constant ofIL-1/3 differs considerably from those reported previously. Anumber
ofworkers (21-23, 35) workingwith murine (21, 23, 35) or human (22) lymphoid
lines have identified receptors for murine IL-I (35) and human IL-la/,Q with
20-50-fold lower affinity (Kd, 2-5 X 10-'° M) than the receptors found for IL-
10on lung fibroblasts. These target cells, like MRC-5 fibroblasts, are nevertheless
reported to require only low picomolar (22, 35) or, in one case (21, 23),
subpicomolar (10-'4 M) concentrations of IL-1 for half-maximal activation.
Accordingly, given the low numbers ofreceptors identified on these cells (100-
250, references 21-23; 1,200, reference 35), few (35) or no (21-23) receptor
molecules would be occupied at the low concentrations of IL-1 at which half-
maximal biological activation is observed . Similarly, it is difficult to explain how
cells bearing receptors of homogeneous affinity respond to IL-1 in dose-respon-
sive fashion when the dynamic range of receptor occupancy between minimum
and maximum biological response amounts to the occupation ofa few receptors.
We therefore propose that the previously reported receptors be considered as
having lowaffinity andsuggest that lymphoid cells thatrespond to low picomolar
or subpicomolar concentrations of IL-1 are likely to bear as-yet-unidentified
higher affinity receptors, such as those found on fibroblasts, that mediate
biological activity.
Recent quantitative molecular studies have strengthened the concept that
monocytes/macrophages found in chronic inflammatory lesions might pro-
foundly influence connective tissue metabolism by producing IL-1 . Three key
facts have emerged from these studies. First, monocytesare highly specialized to
make IL-lf3 in that 1% of the mRNA found in activated cells encodes this
molecule (17, 37). Second, only low picomolar concentrations of IL-1 are
required to induce eicosanoid production, proteaseproduction, and proliferation
by connective tissue cells (20). Third, as shown in the current study, connective
tissue cells bear high-affinity receptors that enable them to respond to extremely
low concentrations of IL-1 in their environment. These data, taken together
with numerous biological studies documenting the effects of IL-1 on connective
tissues (4-13), suggest that the connective tissue destruction and remodeling that
is observed in chronically inflammed tissue may be IL-1 mediated and that
blockade of the IL-1-R on connective tissue cells may be useful in the manage-
ment of chronic inflammatory diseases.
Summary
Native human IL-1# and IL-la stimulated prostaglandin E2 secretion by
human embryonic lung fibroblasts at half-maximal concentrations of 3 ± 1.2 pM
(± SEM) and 10 ± 2.3 pM, respectively. In contrast to the 20-50-fold lower
affinities previously found for IL-1-R on 3T3 cells as well as murine and human
lymphoblastoid lines (ref. 21-23, 35), monoiodo '25I-IL-10 bound to normal
human fibroblasts with a Kd of8.4 ± 4.1 pM in direct binding experiments, and
with a K; of 11.2 ± 2.8 pM in competitive binding experiments. IL-la bound to
the receptor identified by '25I-IL-10 with a K; of 50 ± 18 pM. The receptor84
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exhibited homogeneous affinity for IL-la or IL-la. The receptor did not
recognize IL-2, IFN--y, tumor necrosis factor a, a functionally related monokine,
or bovine acidic fibroblast growth factor, a structurally related mediator. Com-
parison of the biological response curves and binding curves obtained for IL-la
and IL-la showed that they were parallel and that 10-15% occupancy of the
estimated 3,000 sites by either species of IL-1 was sufficient to give half-maximal
stimulation of prostaglandin E2 secretion . Thus, the amount of apparent signal
amplification observed on fibroblasts was considerably lower than the 100-
100,000 fold amplification previously reported for lymphoid lines. Crosslinking
experiments revealed a major band with a corrected molecular mass of ^-80 kD
and a minor band of -200 kD. Labeling of these bands was blocked by IL-1/3
and IL-1a but not by IL-2, IFN-'Y, or tumor necrosis factor a. These results
demonstrate that normal human embryonic lung fibroblasts bear IL-1-R of
sufficiently high affinity to mediate their biological responsiveness to low pico-
molar concentrations of IL-10 and IL-la and are consistent with the existence
of a single receptor mediating the biological properties of both human IL-1
species.
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